Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C

Özet

The incidence of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is 5%-15%, and HCV is an important risk factor for posttransplant kidney issues. Novel interferon-free regimens with direct-acting oral antiviral agents have extremely high response rates in solid organ transplant patients with HCV; however, drug–drug interactions, particularly with immunosuppressive agents, should be considered when deciding the treatment. Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.